ALZHEIMER’S DISEASE AND RELATED DISORDERS AS
Alzheimer’s Disease and Related Disorders as a Global Health Crisis: Challenges and Opportunities
Nahid Rahmani1 and Tareq Al-Dmour2
1Faculty of Medicine, University of Jordan, Amman, Jordan
2Department of Internal Medicine, King Abdullah University Hospital, Amman, Jordan
Corresponding Author: N. Rahmani
Email: [email protected]
Abstract
Alzheimer’s disease (AD) and related disorders (ARD) are a global health crisis. The prevalence of AD has been increasing steadily, with an estimated 50 million people worldwide currently affected. The economic burden of AD and ARD is estimated to be in the trillions of dollars, and the social and psychological burden is immense. The diagnosis of AD and ARD is challenging, and the available treatment options are limited. The lack of effective preventive measures and treatments has led to an increased focus on research to identify new interventions and strategies. This article aims to review the current state of AD and ARD, including their epidemiology, diagnosis, and management, and to identify potential challenges and opportunities for improving patient care. We also discuss the need for increased research and clinical trials to identify effective treatments and preventive measures.
Keywords: Alzheimer’s disease, Related disorders, Global health crisis, Challenges, Opportunities
Introduction
Alzheimer’s disease (AD) and related disorders (ARD) are chronic neurodegenerative diseases that are a global health crisis. AD is the most common form of dementia and is characterised by progressive cognitive decline, impaired memory and language, and changes in behaviour and personality. The prevalence of AD has been increasing steadily over the past few decades, with an estimated 50 million people worldwide currently affected (Alzheimer’s Disease International, 2019).
The economic burden of AD and ARD is immense, with the annual cost of care estimated to be in the trillions of dollars (Alzheimer’s Association, 2020). In addition to the financial burden, the social and psychological impact of AD and ARD on affected individuals and their families is immense. The diagnosis of AD and ARD is challenging, and the available treatment options are limited.
This article aims to review the current state of AD and ARD, including their epidemiology, diagnosis, and management, and to identify potential challenges and opportunities for improving patient care. We also discuss the need for increased research and clinical trials to identify effective treatments and preventive measures.
Epidemiology
The prevalence of AD and ARD is increasing steadily, with an estimated 50 million people currently affected worldwide (Alzheimer’s Disease International, 2019). It is estimated that the number of people affected by AD and ARD will double every 20 years (Alzheimer’s Association, 2020). The prevalence of AD and ARD is higher in older age groups, with the highest prevalence in people aged 85 and over (Alzheimer’s Disease International, 2019).
AD and ARD are more common in women than in men, with a female to male ratio of 2:1 (Alzheimer’s Disease International, 2019). The incidence of AD and ARD also varies by region, with higher rates in developed countries compared to developing countries (Alzheimer’s Association, 2020).
Diagnosis
The diagnosis of AD and ARD is challenging due to the lack of definitive diagnostic tests. The diagnosis is based on a combination of clinical evaluation, laboratory tests, and imaging studies. Clinical evaluation includes a detailed medical history and physical examination, as well as cognitive and functional assessments.
Laboratory tests are used to rule out other conditions that may be causing symptoms similar to those of AD and ARD. Imaging studies such as magnetic resonance imaging (MRI) and computed tomography (CT) can be used to assess brain structure and detect changes associated with AD and ARD.
Management
The management of AD and ARD is focused on symptom relief and slowing disease progression. Currently available medications are aimed at relieving symptoms such as memory loss, confusion, and agitation. Cholinesterase inhibitors are commonly used to improve cognitive function and reduce symptoms of confusion and agitation.
Other medications are used to treat specific symptoms such as depression, anxiety, and sleep disturbances. Non-pharmacological interventions such as cognitive stimulation therapy and social activities can also be used to improve cognitive function and quality of life.
Challenges and Opportunities
Despite recent advances in the diagnosis and management of AD and ARD, there are still many challenges and opportunities for improvement. The lack of effective preventive measures and treatments has led to an increased focus on research to identify new interventions and strategies.
The need for additional research into the pathophysiology of AD and ARD is also essential. This will allow for the development of targeted therapies and improved diagnostic tests. In addition, clinical trials are needed to evaluate the safety and efficacy of existing and emerging treatments.
Conclusion
AD and ARD are a global health crisis, with an estimated 50 million people currently affected worldwide. The economic burden of AD and ARD is immense, and the social and psychological impact on affected individuals and their families is immense. The diagnosis of AD and ARD is challenging, and the available treatment options are limited.
The lack of effective preventive measures and treatments has led to an increased focus on research to identify new interventions and strategies. The need for additional research into the pathophysiology of AD and ARD and the evaluation of existing and emerging treatments is essential.
References
Alzheimer’s Association. (2020). Facts & Figures: The State of Alzheimer’s Disease in 2020. Retrieved from https://www.alz.org/media/HomeOffice/AlzheimersFactsFigures2020.pdf
Alzheimer’s Disease International. (2019). World Alzheimer’s Report 2019. Retrieved from https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf
